Judith A Fox Selected Research

N- (5- (((5- (1,1- dimethylethyl)- 2- oxazolyl)methyl)thio)- 2- thiazolyl)- 4- piperidinecarboxamide

6/2010	Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.
9/2009	SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.
5/2009	Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Judith A Fox Research Topics

Disease

11	Neoplasms (Cancer) 10/2022 - 05/2002
7	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2018 - 04/2010
5	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2022 - 05/2009
2	Stomatitis 09/2015 - 02/2015
2	Multiple Myeloma 06/2010 - 09/2009
2	Ovarian Neoplasms (Ovarian Cancer) 04/2010 - 04/2010
1	Necrosis 05/2017
1	Glioblastoma (Glioblastoma Multiforme) 05/2017
1	Neutropenia 09/2015
1	Pneumonia (Pneumonitis) 09/2015
1	Sepsis (Septicemia) 09/2015
1	Febrile Neutropenia 09/2015
1	Cardiotoxicity 02/2015
1	Leukemia 10/2010
1	Headache (Headaches) 04/2008
1	Fatigue 04/2008
1	Melanoma (Melanoma, Malignant) 04/2008
1	Diarrhea 04/2008
1	Vomiting 04/2008
1	Nausea 04/2008
1	Hypertension (High Blood Pressure) 04/2008
1	Anorexia 04/2008
1	Reperfusion Injury 01/2002

Drug/Important Bio-Agent (IBA)

8	vosaroxinIBA 11/2018 - 04/2010
6	QuinolonesIBA 05/2017 - 04/2010
5	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2018 - 10/2010
3	Agammaglobulinaemia Tyrosine KinaseIBA 10/2022 - 01/2022
3	vecabrutinibIBA 10/2022 - 01/2022
3	Type II DNA Topoisomerases (Topoisomerase II)IBA 09/2016 - 04/2010
3	N- (5- (((5- (1,1- dimethylethyl)- 2- oxazolyl)methyl)thio)- 2- thiazolyl)- 4- piperidinecarboxamideIBA 06/2010 - 05/2009
2	DNA (Deoxyribonucleic Acid)IBA 09/2016 - 02/2015
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 09/2009 - 05/2009
2	Proteins (Proteins, Gene)FDA Link 03/2006 - 05/2002
1	ibrutinibIBA 10/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Temozolomide (Temodar)FDA LinkGeneric 05/2017
1	AntigensIBA 12/2016
1	Gemtuzumab (Mylotarg)FDA Link 12/2016
1	IronIBA 02/2015
1	AnthracyclinesIBA 02/2015
1	PlatinumIBA 04/2010
1	4- amino- 5- fluoro- 3- (5- (4- methylpiperazin- 1- yl)- 1H- benzimidazol- 2- yl)quinolin- 2(1H)- oneIBA 04/2008
1	Alkaline PhosphataseIBA 04/2008
1	Pharmaceutical PreparationsIBA 04/2008
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2008
1	tumor-associated antigen 72IBA 03/2006
1	ProdrugsIBA 03/2006
1	CarbohydratesIBA 03/2006
1	EpitopesIBA 03/2006
1	Death Domain ReceptorsIBA 05/2002
1	Irinotecan (Camptosar)FDA LinkGeneric 05/2002
1	Topoisomerase I InhibitorsIBA 05/2002
1	LigandsIBA 05/2002
1	IntegrinsIBA 01/2002
1	adhesion receptorIBA 01/2002

Therapy/Procedure

1	Immunotherapy 12/2016
1	Therapeutics 04/2010